Article Sidebar
Published:
Sep 21, 2015Keywords:
Article Details
Copyright for articles published in this journal is retained by the journal.
SAJChem applies the Creative Commons Attribution (CC BY) license to manuscripts we publish. This license was developed to facilitate open access – namely, free immediate access to, and unrestricted reuse of, original works of all types. Under this license, authors agree to make articles legally available for reuse, without permission or fees, for virtually any purpose. Anyone may copy, distribute or reuse these articles, as long as the author and original source are properly cited.
Main Article Content
Synthesis, Crystal Structure and Anti-ischaemic Activity of (E)-1-{4-[Bis(4-methoxy-phenyl)methyl]piperazin-1-yl}- 3-(4-chlorophenyl)-prop-2-en-1-one
Abstract
The title compound (E)-1-{4-[bis(4-methoxyphenyl)methyl]piperazin-1-yl}-3-(4-chloro- phenyl)prop-2-en-1-one (C28H29ClN2O3, Mr = 476.98) (5) was synthesized and studied by the single crystal X-ray diffraction method. Its structure was confirmed by 1HNMR, 13CNMR,HRMSand X-ray single crystal structure determination. Compound 5 crystallized in the monoclinic system, space group P21/c with a=10.392(2), b=7.9180(16), c=30.474(6) Å, β=97.78(3) °, V=2484.4(9)Å3,Z=4, Dc=1.275 g cm–3, F(000)= 1008, μ=0.186mm–1,MoKá radiation (ë=0.71073 Å), R=0.0692 andwR=0.1469 for 2046 observed reflections with I<2ó(I). The title compound was screened for the anti-ischaemic activity in vivo. The results showed that compound 5 significantly prolonged the survival time of mice subjected to acute cerebral ischaemia at all doses tested and exhibited potent neuroprotective activity.
KEYWORDS: Cinnamide, crystal structure, synthesis, anti-ischaemic activity.
